Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor

Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor

US Patent 11031102 · Granted Jun 8, 2021

Estimated economic value: $184,609,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Methods for treatment of refractory generalized myasthenia gravis2025
Dosage and administration of anti-C5 antibodies for treatment of protein-losing 2022
Risk evaluation and management strategy involving patient follow-ups relating to2022
Risk evaluation and management strategy involving patient follow-ups relating to2022
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of com2020
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of com2020
Methods for treating complement-associated disorders2017
Methods for treating complement-associated disorders2017
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of com2017
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of com2017
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of com2017
Methods and compositions for treating complement-associated disorders2016